JP2012072157A5 - - Google Patents

Download PDF

Info

Publication number
JP2012072157A5
JP2012072157A5 JP2011242133A JP2011242133A JP2012072157A5 JP 2012072157 A5 JP2012072157 A5 JP 2012072157A5 JP 2011242133 A JP2011242133 A JP 2011242133A JP 2011242133 A JP2011242133 A JP 2011242133A JP 2012072157 A5 JP2012072157 A5 JP 2012072157A5
Authority
JP
Japan
Prior art keywords
composition
immunostimulatory complex
dextran
deae
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011242133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012072157A (ja
Filing date
Publication date
Priority claimed from AUPP8073A external-priority patent/AUPP807399A0/en
Application filed filed Critical
Publication of JP2012072157A publication Critical patent/JP2012072157A/ja
Publication of JP2012072157A5 publication Critical patent/JP2012072157A5/ja
Pending legal-status Critical Current

Links

JP2011242133A 1999-01-08 2011-11-04 改良サポニンアジュバント組成物およびそれに関する方法 Pending JP2012072157A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8073 1999-01-08
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000593330A Division JP4949555B2 (ja) 1999-01-08 1999-12-24 改良サポニンアジュバント組成物およびそれに関する方法

Publications (2)

Publication Number Publication Date
JP2012072157A JP2012072157A (ja) 2012-04-12
JP2012072157A5 true JP2012072157A5 (cg-RX-API-DMAC7.html) 2012-05-31

Family

ID=3812278

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000593330A Expired - Lifetime JP4949555B2 (ja) 1999-01-08 1999-12-24 改良サポニンアジュバント組成物およびそれに関する方法
JP2011242133A Pending JP2012072157A (ja) 1999-01-08 2011-11-04 改良サポニンアジュバント組成物およびそれに関する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000593330A Expired - Lifetime JP4949555B2 (ja) 1999-01-08 1999-12-24 改良サポニンアジュバント組成物およびそれに関する方法

Country Status (15)

Country Link
US (2) US9579379B1 (cg-RX-API-DMAC7.html)
EP (2) EP1140165B1 (cg-RX-API-DMAC7.html)
JP (2) JP4949555B2 (cg-RX-API-DMAC7.html)
AT (1) ATE410183T1 (cg-RX-API-DMAC7.html)
AU (2) AUPP807399A0 (cg-RX-API-DMAC7.html)
CA (2) CA2660344A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108693T1 (cg-RX-API-DMAC7.html)
DE (1) DE69939706D1 (cg-RX-API-DMAC7.html)
DK (1) DK1140165T3 (cg-RX-API-DMAC7.html)
ES (1) ES2317708T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ512011A (cg-RX-API-DMAC7.html)
PT (1) PT1140165E (cg-RX-API-DMAC7.html)
TW (1) TW533079B (cg-RX-API-DMAC7.html)
WO (1) WO2000041720A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200105543B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
AU2005335104C1 (en) * 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2609244A1 (en) * 2005-06-01 2006-12-07 Pfizer Products Inc. Vaccine compositions and methods for the treatment of urinary incontinence
WO2008110912A1 (en) * 2007-03-14 2008-09-18 Pfizer Inc. Fertility regulation in horses
SG10201400388QA (en) 2008-12-09 2014-05-29 Pfizer Vaccines Llc IgE CH3 peptide vaccine
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
MX2012001194A (es) 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
ES2963147T3 (es) * 2011-05-13 2024-03-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
JP6281163B2 (ja) 2011-08-22 2018-02-21 エメルゲント バイオソリューションズ カナダ クロストリジウム・ディフィシレ抗体
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
CA3060664A1 (en) 2013-09-19 2015-03-26 Zoetis Services Llc Water-in-oil emulsions comprising immunostimulatory oligonucleotides
KR20160077214A (ko) 2013-12-16 2016-07-01 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 g 당단백질 면역원성 조성물
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
KR20170041167A (ko) 2014-02-19 2017-04-14 조디 베리 마르부르크 단클론성 항체
JP2017512759A (ja) 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
LT3244920T (lt) * 2015-01-16 2023-08-25 Zoetis Services Llc Snukio ir nagų ligos vakcina
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
AU2016295566B2 (en) 2015-07-21 2019-06-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017185089A2 (en) 2016-04-22 2017-10-26 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ,インコーポレイテッド ヒト抗体、医薬組成物及び方法
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔(苏州)生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
CA3243932A1 (en) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. PAN-PNEUMOVIRUS VACCINE COMPOSITIONS AND THEIR METHODS OF USE
WO2025010482A1 (pt) * 2023-07-07 2025-01-16 Ouro Fino Saúde Animal Ltda Peptídeo de gnrh modificado e seu conjugado para imunocastração de mamíferos, método de fabricação, composição e kit
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1924304C3 (de) * 1969-05-13 1980-07-17 Bayer Ag, 5090 Leverkusen Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
WO1988005308A1 (en) 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Anti reproductive hormone
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
US4892830A (en) * 1987-04-02 1990-01-09 Baylor College Of Medicine Environmentally controlled in vitro incubator
GB2228262B (en) 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
DE69027983T2 (de) * 1989-08-25 1997-03-20 Biotech Australia Pty Ltd Fusionsproteine bestehend aus TraTp und mindestens einem LHRH-Analog
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU7468196A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
AUPP060097A0 (en) * 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response

Similar Documents

Publication Publication Date Title
JP2012072157A5 (cg-RX-API-DMAC7.html)
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
RU2012138368A (ru) 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком
HRP20140484T1 (hr) Cjepivni pripravci koji sadrže saponinski adjuvans
BR112014032091A8 (pt) Composição imunogênica multivalente, e composição farmacêutica para induzir uma resposta imune a um conjugado de polissacarídeo capsular de streptococcus pneumoniae
JP2012224636A5 (cg-RX-API-DMAC7.html)
JP2014506916A5 (cg-RX-API-DMAC7.html)
JP2018514534A5 (cg-RX-API-DMAC7.html)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2011518170A5 (cg-RX-API-DMAC7.html)
FI3244917T3 (fi) Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
JP2015522573A5 (cg-RX-API-DMAC7.html)
JP2016040284A5 (cg-RX-API-DMAC7.html)
JP2010525050A5 (cg-RX-API-DMAC7.html)
BR112015013560A2 (pt) composição imunogênica multivalente; e composição farmacêutica para induzir uma resposta imunológica aos conjugados de polissacarídeo capsular de streptococcus pneumoniae
GB201101665D0 (en) Immunogenic compositions
IN2012DN00407A (cg-RX-API-DMAC7.html)
HRP20141258T1 (hr) 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat
WO2009089535A3 (en) Polypeptide vaccine and vaccination strategy against mycobacterium
WO2013132452A3 (en) Neisseria meningitidis compositions and methods thereof
JP2016516801A5 (cg-RX-API-DMAC7.html)
HRP20230359T1 (hr) Imunogeni pripravak
BR112015004593A2 (pt) composições imunogênicas
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2010063476A3 (en) Solid dosage forms of bendamustine